Levetiracetam Eugia

Levetiracetam, the active ingredient in Levetiracetam Eugia, is an anticonvulsant presented as an injectable solution for intravenous use. It is employed to manage epilepsy, including both partial and generalized seizures, in patients who require rapid or controlled drug delivery. The formulation complies with EU regulatory standards and is indicated for hospital and clinical settings where intravenous therapy is preferred.

GNH USA supplies Levetiracetam Eugia as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levetiracetam is an antiepileptic drug that modulates neuronal excitability to control seizure activity. - Epilepsy: reduces the frequency and severity of seizures in patients with diagnosed epilepsy. - Partial seizures: provides effective control of focal onset seizures, with or without secondary generalisation. - Generalized seizures: helps prevent tonic‑clonic and other generalized seizure types in appropriate patients.

Levetiracetam may cause a range of adverse reactions, from mild to severe. Monitoring and prompt reporting of any unexpected symptoms are recommended.

Common Side Effects: - Dizziness: transient sensation of light‑headedness or unsteadiness. - Fatigue: feeling unusually tired or lacking energy. - Somnolence: increased sleepiness or drowsiness. - Headache: mild to moderate head pain. - Irritability: mood changes including increased agitation. - Nausea: mild gastrointestinal discomfort.

Serious or Rare Side Effects: - Severe allergic reactions: rash, swelling, or anaphylaxis requiring immediate medical attention. - Stevens‑Johnson syndrome: rare but serious skin disorder with blistering. - Blood dyscrasias: abnormal blood counts such as leukopenia or thrombocytopenia. - Suicidal thoughts or behavior: emergence of depressive symptoms or suicidal ideation. - Severe depression or mood disturbances: significant changes in emotional state. - Rash with systemic involvement: may indicate a hypersensitivity reaction.

Levetiracetam requires careful consideration of patient‑specific factors and proper handling of the injectable product. - Renal impairment: dose adjustment may be needed based on renal function. - Hepatic impairment: monitor liver enzymes and consider dose modification. - Pregnancy: safety category unknown; weigh potential benefits against risks. - Concomitant CNS depressants: may enhance sedation or respiratory depression. - Mood changes: observe for signs of depression, irritability, or suicidal thoughts. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Levetiracetam can interact with several medications, affecting its efficacy or safety.

Major Interactions (Avoid): - Carbamazepine: enzyme induction may lower levetiracetam levels. - Phenytoin: may reduce levetiracetam plasma concentrations. - Phenobarbital: strong inducer that can decrease therapeutic effect.

Moderate Interactions (Monitor Closely): - Valproate: may increase risk of adverse CNS effects. - Other antiepileptics (e.g., lamotrigine): monitor for additive sedation. - Alcohol: can potentiate central nervous system depression. - Ritonavir: may modestly reduce levetiracetam exposure. - Oral contraceptives: monitor for reduced efficacy, though interaction is minimal.